HR Execs on the Move

Lannett Company

www.lannett.com

 
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.lannett.com
  • 9000 State Rd
    Philadelphia, PA USA 19136
  • Phone: 215.333.9000

Executives

Name Title Contact Details
Tony Meehan
Chief Financial Officer Profile
Timothy Niedrist
Associate Director of Financial Operations Profile
Ajit Roy
Senior Director of Clinical R&D Profile
Helen Libman
Senior Director, Analytical R&D Profile

Similar Companies

Aerodyne Research

Aerodyne Research is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bradford Health Services

Its never easy to admit that you or someone you care about is addicted to alcohol or drugs. But once you recognize the problem, the road to recovery appears at your feet. The first step down that road is to find professional help.

MBC Pharma (Main)

MBC Pharma (Main) is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AMGIT

AMGIT is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.